Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-c9gpj Total loading time: 0 Render date: 2024-07-11T05:15:00.707Z Has data issue: false hasContentIssue false

Medications to Treat Neurodegenerative Diseases

from Section 2 - Medication Adverse Effects

Published online by Cambridge University Press:  30 May 2019

By
Angela M. Hill ,
Jasmine B. R. Cutler  and
Kristin Robinson
Edited by
Alan B. Ettinger ,
Deborah M. Weisbrot  and
Casey E. Gallimore
Alan B. Ettinger
Affiliation:
Safe Passage Diagnostics, New York
Deborah M. Weisbrot
Affiliation:
State University of New York, Stony Brook
Casey E. Gallimore
Affiliation:
University of Wisconsin
Get access
Type
Chapter
Information
Synopsis of Neurology, Psychiatry and Related Systemic Disorders , pp. 767 - 773
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amantadine. Clinical Pharmacology [Internet]. Tampa, FL: Elsevier. 2017. Available from www.clinicalpharmacology.com. Accessed Aug 14, 2017.Google Scholar
Chen, JJ, Dashtipour, K. Parkinson disease. In DiPiro, JT, Talbert, RL, Yee, GC, et al., eds. Pharmacotherapy: a pathophysiologic approach. 10th ed. New York, NY: McGraw-Hill; 2017: p. 895. http://accesspharmacy.mhmedical.com.ezproxy.hsc.usf.edu/content.aspx?bookid=1861&sectionid=134127873. Accessed Aug 14, 2017.Google Scholar
Lexicomp Online, Lexi-Drugs Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; Aug 14, 2017.Google Scholar
Spritzer, SD, Kinney, CL, Condie, J, et al. Amantadine for patients with severe traumatic brain injury: a critically appraised topic. Neurologist. 2015; 19: 61–4.Google Scholar
Stinton, C, McKeith, I, Taylor, JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015; 172: 731–42.CrossRefGoogle ScholarPubMed
Symmetrel® (amantadine hydrochloride) package insert. Chadds Ford, PA. Endo Pharmaceuticals Inc.; Jan 2009.Google Scholar
American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015; 63: 2227–46.Google Scholar
Cai, X, Campbell, N, Khan, B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013; 9: 377–85.Google Scholar
Fox, C, Richardson, K, Maidment, ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Aging Study. J Am Geriatr Soc. 2011; 59: 1477–83.Google Scholar
Haft, S, Farquhar, D, Carey, R, Mirza, N. Anticholinergic use is a major risk factor for dysphonia. Ann Otol Rhinol Laryngol. 2015; 124: 797–802.Google Scholar
Kara, Ő, Arik, G, Kizilarslanoglu, MC, et al. Potentially inappropriate prescribing according to the STOPP/START criteria for older adults. Aging Clin Exp Res. 2016; 28: 761–8.CrossRefGoogle Scholar
Mintzer, J, Burns, A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000; 93: 457–462.Google Scholar
Salahudeen, MS, Duffull, SB, Nishtala, PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015; 15: 31.Google Scholar
Burn, D. Parkinson's disease: treatment. The Pharmaceutical Journal. 2000; 264: 476–9.Google Scholar
Chen, JJ, Swope, D. Parkinson's disease. In DiPiro, JT, Talbert, RL, Yee, GC, et al., eds. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill Education/Medical; 2014: Chapter 43.Google Scholar
Entacopone. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Feb 26, 2016.Google Scholar
Jankovic, J, Aguillar, L. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008; 4: 743–57.Google Scholar
Müller, T. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Drugs. 2015; 75: 157–74.Google Scholar
Tolcapone. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Feb 26, 2016.Google Scholar
Agboton, C, Mahdavian, S, Singh, A, Ghazvini, P, Hill, A, et al. Impact of nighttime donepezil administration on sleep in the older adult population: a retrospective study. Mental Health Clinician. 2014; 4: 95.Google Scholar
Alzheimer's Disease. Pharmacotherapy. A Pathophysiologic Approach. 2014. McGraw Hill Companies.Google Scholar
Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; 25: CD005593.Google Scholar
Chitnis, S, Rao, J. Rivastigmine in Parkinson's disease dementia. Expert Opin Drug Metab Toxicol. 2009; 5: 941–55.Google Scholar
Dwolatzky, T, Clarfield, A. Cholinesterase inhibitors and memantine in more advanced Alzheimer's disease. The debate continues. Aging Health. 2012; 8: 233–7.Google Scholar
Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004; 351: 2509–18.Google Scholar
Howard, R, McShane, R, Lindesay, J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012; 366: 893–903.Google Scholar
Lockhart, I, Mitchell, S, Kelly, S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systemic review of the “real-world” evidence. Dement Geriatr Cogn Disord. 2009; 28: 389–403.Google Scholar
Burn, D. Parkinson's disease: treatment. Pharm J. 2000; 264: 476–9.Google Scholar
Chen, JJ, Swope, D. Parkinson's disease. In DiPiro, JT, Talbert, RL, Yee, GC, et al., eds. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill Education/Medical; 2014. Chapter 43.Google Scholar
Jankovic, J, Aguillar, L. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008; 4: 743–57.Google Scholar
Moore, T, Glenmullen, J, Mattison, D. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014; 174: 1930–3.Google Scholar
Pérez-Pérez, J, Pagonabarraga, J, Martínez-Horta, S, et al. Head-to-head comparison of the neuropsychiatric effect of dopamine agonists in Parkinson's disease: a prospective, cross-sectional study in non-demented patients. Drugs Aging. 2015; 32(5): 401–7.Google Scholar
Weiss, H, Pontone, G. Dopamine receptor agonist drugs and impulse control disorders. JAMA Intern Med. 2014; 174(12): 1935–7.Google Scholar
Chen, JJ, Dashtipour, K. Parkinson disease. In DiPiro, JT, Talbert, RL, Yee, GC, et al. eds. Pharmacotherapy: a pathophysiologic approach. 10th ed. New York, NY: McGraw-Hill; 2017: p. 895. http://accesspharmacy.mhmedical.com.ezproxy.hsc.usf.edu/content.aspx?bookid=1861&sectionid=134127873. Accessed Aug 14, 2017.Google Scholar
Jankovic, J, Aguillar, L. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008; 4: 743–57.Google Scholar
Lexicomp Online, Lexi-Drugs Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. Accessed Aug 14, 2017.Google Scholar
Sinemet® (carbidopa levodopa tablets) package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; Jul 2014.Google Scholar
Stalevo® (carbidopa, levodopa and entacapone tablets) package insert. East Hanover, New Jersey. Novartis Pharmaceuticals Inc.; Feb 2016.Google Scholar
Thanvi, B, Lo, N, Robinson, T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007; 83: 384–8.Google Scholar
Albrecht, H, Dieterich, M, Pöllmann, W, Starck, M, Straube, A. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1996; 244: 9–16.Google Scholar
Lexicomp Online, Lexi-Drugs Online. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; Aug 14, 2017.Google Scholar
Matsunaga, S, Kishi, T, Iwata, N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PloS One. 2015; 10: e0123289.Google Scholar
Memantine. Clinical Pharmacology [Internet]. Tampa, FL: Elsevier; 2017. Available from: www.clinicalpharmacology.com. Accessed Aug 14, 201.Google Scholar
Namenda (memantine hydrochloride) extended release capsule package insert. New York City, NY: Forest Pharmaceuticals, Inc.; Jun 2016.Google Scholar
Robinson, DM, Keating, GM. Memantine: a review of its use in Alzheimer's disease. Drugs. 2006; 66: 1515–34.Google Scholar
Shi, X, Lin, X, Hu, R, Sun, N, Hao, J, Gao, C. Toxicological differences between NMDA receptor antagonists and cholinesterase inhibitors. Am J Alzheimers Dis Other Demen. 2016; 31: 405–12.Google Scholar
Zdanys, K, Tampi, RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 1362–74.CrossRefGoogle ScholarPubMed
Coles, A. Newer therapies for multiple sclerosis. Ann Indian Acad Neurol. 2015; 18(Suppl 1): S30–34.Google Scholar
Fabis-Pedrini, MJ, Xu, W, Burton, J, et al. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment. J Clin Neurosci. 2016; 25: 145–7.Google Scholar
Lexicomp Online, Lexi-Drugs Online. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; Aug 14, 2017.Google Scholar
Natalizumab. Clinical Pharmacology [Internet]. Tampa, FL: Elsevier; 2017. www.clinicalpharmacology.com. Accessed Aug 14, 2017.Google Scholar
Plavina, T, Subramanyam, M, Bloomgren, G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014; 76: 802–12.Google Scholar
Rommer, PS, Dudesek, A, Stuve, O, et al. Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol. 2014; 175: 373–84.Google Scholar
Tysabri® (natalizumab) injection package insert. Cambridge, MA: Biogen, Idec Inc.; May 2016.Google Scholar
Armstrong, MJ, Miyasaki, JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012; 79: 597–603.Google Scholar
Coric, V, Taskiran, S, Pittenger, C, et al. Riluzole augmentation in treatment-resistant obsessive–compulsive disorder: an open-label trial. Biol Psych. 2005; 58: 424–8.Google ScholarPubMed
Miller, R, Jackson, C, Kasarskis, E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2009: 73: 1218–26.Google Scholar
Phuken, J, Hardiman, O. The management of amyotrophic lateral sclerosis. J Neurol. 2009; 256: 176–86.Google Scholar
Pollack, M. Refractory generalized anxiety disorder. J Clin Psych. 2009; 70(Suppl 2): 32–8.Google Scholar
Rilutek (riluzole) tablet [product information]. Laval, Quebec: Sanofi-aventis Canada, Inc; May 2010.Google Scholar
Rilutek. In RxList®. WebMD, LLC. www.rxlist.com. Accessed Jan 28, 2016.Google Scholar
Sanacora, G, Kendell, S, Levin, Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007; 61: 822–5.CrossRefGoogle ScholarPubMed
DiPiro, JT. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill Medical; 2014.Google Scholar
Kertesz, DP, Swartz, MV, Tadger, S, et al. Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study. Clin Neuropharmacol. 2015; 38: 23–5.Google Scholar
Margolis, RL. Tetrabenazine, depression and suicide: good news. J Huntingtons Dis. 2014; 3: 137–8.Google Scholar
Mehanna, R, Hunter, C, Davidson, A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013; 28: 210–15.CrossRefGoogle ScholarPubMed
Xenazine® (tetrabenazine tablets) package insert. Washington, DC: Prestwick Pharmaceuticals; May 2008.Google Scholar
Xenazine. In RxList®. WebMD, LLC. www.rxlist.com. Accessed Feb 3, 2016.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×